Skip to main content
. Author manuscript; available in PMC: 2015 Apr 30.
Published in final edited form as: J Eval Clin Pract. 2015 Jan 6;21(2):300–306. doi: 10.1111/jep.12308

Table 2.

χ2 comparison of co-morbidities between phase 1 and phase 3

Descriptor Phase 1 sample
(n = 100) (%)		 Phase 3 sample
(n = 100) (%)		 χ2 Significance
Hypertension 42 38 0.33 0.67
Diabetes 21 18 0.29 0.72
Dyslipidaemia 27 35 1.50 0.28
Mood disorder 22 14 2.17 0.20
Osteoarthritis 12   9 0.48 0.64
CHD   5 12 3.15 0.13
Stroke   1   1 0.00 1.00
Sleep apnoea   2   1 0.34 1.00

CHD, coronary heart disease.